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Abstract: Purpose: To evaluate the response to therapy with PET-CT in metastatic colorectal cancer patients treated 
with Bevacizumab and chemotherapy. 
Methods: Twenty-two patients with metastatic colorectal cancer that were treated with bevacizumab and 6 cycles of 
chemotherapy were evaluated by whole-body PET-CT scan before and after the treatment in accordance with the 
European Organization for Research and Treatment of Cancer criteria. 
Results: While 31.8% of patients responded to treatment (complete response + partial response), 68.2% did not respond 
to treatment (stable disease + progressive disease). The mean hepatic, extra hepatic, abdomen, lung and bone 
metastases SUVmax values were higher after treatment in comparison to the pre-treatment values. There was an 
increase in SUVmax values in those who did not respond to the treatment, while a decrease was observed in those who 
responded to the treatment. Survival was significantly increased in all patients that responded to the treatment. The 
difference in terms of gender, histological subtype, histological grade, primary tumor location, presence of metastases in 
regional lymph nodes and liver at the time of diagnosis or the response to the treatment was not statistically significant.  
Conclusions: In this study we detected metabolic response before anatomical response with PET-CT in one third of 
metastatic colorectal cancer patients treated with Bevacizumab and chemotherapy. This finding suggests that PET-CT 
may be used as a measure to follow therapy response and predict the prognosis in metastatic colorectal cancer patients. 
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INTRODUCTION 
Colorectal cancer is the most common cancer of the 
gastrointestinal tract. The diagnosis of colorectal 
carcinoma is based on colonoscopy and biopsy. The 
preoperative staging with imaging modalities is usually 
limited because most patients will benefit from 
colectomy to prevent intestinal obstruction. The extent 
of the disease can be evaluated during surgery.  
Positron emission tomography with 2-deoxy-2-
[fluorine-18]fluoro-D-glucose integrated with computed 
tomography (F-18 FDG PET-CT) is a popular hybrid 
imaging method used in the evaluation of oncological 
patients. It is superior to all other radiological methods 
because of its ability to show metabolic/functional 
changes in the tumor tissue in the early stages, when 
morphological changes have not yet occurred [1-3]. 
PET-CT has been widely used in diagnosis, staging, 
restaging, evaluation of response to therapy, planning  
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of the radiotherapy and chemosensitivity determination 
in many types of cancer [1-7]. 
Vascular endothelial growth factor (VEGF) is the 
most potent and specific angiogenic factor that 
regulates normal and pathological angiogenesis. 
Increased expression of VEGF is associated with 
increased risk of metastasis, recurrence and poor 
prognosis in many types of cancers, including 
colorectal cancer [8]. Bevacizumab, which is a 
monoclonal antibody targeted against VEGF, is the first 
anti-angiogenic agent approved by the American Food 
and Drug Administration for use in patients with 
metastatic colorectal cancer [9-11]. 
Our aim in this study was to evaluate colorectal 
cancer patients’ response to bevacizumab and 
chemotherapy by using PET-CT. 
MATERIALS AND METHODS 
The local ethics committee approved the study. The 
mean age of the 22 colorectal cancer patients included 
in our study was 62.8 ± 7.7, and 17 of the patients 
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(77.3%) were male while 5 (22.7%) were female. The 
PET-CT images of 22 patients that were taken before 
and after bevacizumab and 6 cycles of chemotherapy 
treatment [Standard doses of FOLFIRI (irinotecan 180 
mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5-
fluorouracil (FU) bolus 400 mg/m2 day 1, 5-FU infusion 
2400 mg/m2 over 46 h) plus bevacizumab 5 mg/kg on 
day 1 were given on a 14-day cycle] were 
retrospectively evaluated in the workstation. The 
whole-body 18F-FDG PET/CT images were done by 
using a PET/CT scanner (Philips Gemini TF), 
consisting of dedicated lutetium yttrium oxyorthosilicate 
(LYSO) full ring PET scanner and 64 slice CT. 
Standard patient preparation included at least 6 hours 
fasting and serum glucose level of less than 150 mg/dl 
before 18F-FDG administration. PET/CT imaging was 
performed 60 minutes after intravenous injection of 3. 
7MBq/kg (0.1mCi/kg) of 18F-FDG (Monrol, Eczacıbaşı). 
At 60 minute after administration of 18F-FDG, low dose 
CT (50mAs, 120 kV) covering area from scull to the 
mid-thighs was performed for the purpose of 
attenuation correction and precise anatomical 
localization. Subsequently, emission scan was 
acquired immediately following the CT for 2-3 min per 
bed position in the three-dimensional mode. A nuclear 
medicine specialist performed both by visual and semi-
quantitative evaluations PET and CT images (non-
corrected and attenuation-corrected) in the rotating 
maximum-intensity projection and in the cross-sectional 
planes view (transverse-sagittal-coronal).The PET-CT 
results were reported as normal or abnormal FDG 
uptake. The anatomical localization of regions with 
abnormal FDG uptake was clarified with the help of the 
fusion of CT images.  
Pre-treatment PET-CT images were accepted as 
baseline and were compared with post-treatment 
images. The metastatic lesions detected in basal PET-
CT images were evaluated in terms of size and FDG 
uptake after the treatment (Table 1). Moreover, we also 
investigated whether there were new metastatic 
lesions, and made a progression/regression distinction. 
We used the European Organization for Research and 
Treatment of Cancer (EORTC) criteria to evaluate the 
response to the treatment. 
The SPSS 20.0 software package was used for 
statistical analysis of the data. The categorical 
variables were expressed as number and percentage, 
while continuous variables were expressed as mean 
and standard error. The relationship between 
categorical variables (gender, histopathology, 
histological grade, localization and treatment response) 
was evaluated by using the chi-square test. The 
McNemar test was used to evaluate the relationship 
between the presence of metastatic lesions before and 
after the treatment. The Kolmogrov-Smirnov test was 
used to test whether the variables were distribution 
normally and the paired t-test was used to compare the 
parametric data (SUVmax values before and after 
treatment and metastatic lesion size), (Table 2, Figure 
1A-B). The statistical significance level was set to 0.05 
in all tests. 
 
Figure 1(A-B): Boxplot graph showing pre-treatment and 
post-treatment SUVmax values of hepatic (A) and 
extrahepatic (B) metastases and treatment outcomes. 
Table 1: Pre-Treatment and Post-Treatment Distribution 
of Metastases in PET-CT  
Pre-Treatment Post-Treatment 
 
N % N % 
Hepatic Metastasis 10 (45.5) 9 (40.9) 
Extra Hepatic Metastasis 
Abdominopelvic region 
(Peritoneum, lymph 
nodes, mesenteric) 
Lung 
Bone 
 
14 (63.6) 
 
 
9 (40.9) 
5 (22.7) 
 
15 (68.2) 
 
 
9 (40.9) 
5 (22.7) 
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RESULTS 
Adenocarcinoma was the most common histological 
subtype of colorectal cancer (81.8%, N=18), followed 
by mucinous adenocarcinoma (13.6%, N=3) and signet 
ring cell carcinoma (4.5%, N=1). There were 8 (36.4%) 
well differentiated, 11 (50%) moderately differentiated, 
and 3 (13.6%) poorly differentiated cases. In 10 
patients (54.5%) the tumors were localized in rectum, 
while in 12 (45.5%) patients the tumors were localized 
incolon. Twenty-one patients (95.5%) underwent 
surgical treatment, while 1 patient (4.5%) did not. 
During initial diagnosis, 18 patients (81.8%) were 
positive for regional lymph node metastasis, while 5 
patients (22.7%) were positive for liver metastasis. 
Moreover, the comparison of PET-CT scans taken 
before and after treatment showed regression in 7 
cases (31.8%) and progression in 15 cases (68.2%). 
The PET-CT scans taken after the treatment 
showed that liver metastases completely disappeared 
in 3 patients (Figure 2A-D). However, new liver 
metastases were observed in 2 patients who did not 
have liver metastasis in their baseline PET-CT scans 
(Figure 3A-F). 
Table 2: The Evaluation of the Pre-Treatment and Post-Treatment Mean SUVmax Values of Metastatic Colorectal 
Cancer 
Colorectal Cancer 
Metastasis Location PET-CT TIme 
Number of Patients with 
Metastasis (N) 
Mean SUVmax 
Values 
Standard 
Error P Value 
Liver Pre-treatment 10 (45.5%) 7.66 +/- 1.92 
 Post-treatment 9 (40.9%) 8.80 +/- 1.52 
0.473 
Extrahepatic 
abdominopelvic Pre-treatment 14 (63.6%) 11.19 +/- 1.75 
 Post-treatment 15 (68.2%) 13.97 +/- 2.35 
0.244 
Lung Pre-treatment 9 (40.9%) 4.22 +/- 1.26 
 Post-treatment 9 (40.9%) 6.39 +/- 1.36 
0.129 
Bone Pre-treatment 5 (22.7%) 8.90 +/- 2.29 
 Post-treatment 5 (22.7%) 13.48 +/- 5.18 
0.241 
 
      A          B 
 
      C         D 
Figure 2A-D: The pre-treatment (A,C) and post-treatment (B,D) PET-CT scans of the colon cancer patient that had liver 
metastasis before the treatment. 
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When the patients’ extrahepatic metastases were 
evaluated, the basal PET-CT showed abdominopelvic 
(peritoneum, lymph nodes, mesenteric) metastases in 
14 patients (63.6%), while the post-treatment PET-CT 
showed abdominopelvic metastases in 15 patients 
(68.2%). Moreover, the basal and post-treatment PET-
CT showed that 9 patients (40.9%) had metastases in 
the lungs (Figure 4A-F), while 5 patients (22.7%) had 
bone metastasis (Figure 5A-D). 
Seven patients (31.8%) had metabolic response 
(complete response, partial response) to the treatment 
and 15 patients (68.2%) did not have any response to 
the treatment (stable disease, progressive disease). 
There was no significant difference between genders, 
histopathological grade and localization of primary 
tumor in terms of response to the treatment (p = 0.519 
and p = 0.783, p = 0.867). Additionally, we did not find 
any significant difference between the presence of liver 
metastases at the time of initial diagnosis and the 
presence of regional lymph node metastases in terms 
of response to treatment (p = 0.655, p = 0.746). 
The presence, mean SUVmax and metastatic lesion 
size of liver metastases before and after treatment 
were evaluated, and no significant difference was 
detected (p = 1.00, p = 0.473, p = 0.220). The 
presence of lung, extrahepatic abdominopelvic and 
bone metastases before and after the treatment and 
mean SUVmax values were compared and there was 
no significant difference (p = 1.00, p = 0.129, p = 1.00, 
p = 0.244 and p = 1.00, p = 0.241). 
Lastly, those who survived had a significantly higher 
response to treatment than those who did not survive 
(p = 0.008), (Table 3). 
 
     A      B 
 
     C      D 
 
     E      F 
Figure 3A-F: The pre-treatment (A, C, E) and post-treatment PET-CT scans of a colon cancer patient that had developed a new 
metastatic lesion in the liver after the treatment (B, D, F). 
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            A                 B 
 
            C                 D 
 
            E                F 
Figure 4A-F: The pre-treatment (A, C, E) and post-treatment PET-CT scans of a colon cancer patient that had developed a new 
metastatic lesion in the lung after the treatment (B, D, F). 
 
           A            B 
 
           C            D 
Figure 5A-D: The PET-CT scans of post-treatment (B, D) progression in a rectal cancer patient that had bone metastasis before 
the treatment (A, C). 
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Table 3: The Evaluation of Survived and Deceased Patients in Terms of Response to Treatment 
 Survived Deceased (N) P Value 
Responded to treatment 7 (100%) 0 (0%) 7 (31.8%) 
Did not respond to treatment 6 (40%) 9 (60%) 15 (68.2%) 
(N) 13 (59.1%) 9 (40.9%) 22 (100%) 
0.008 
 
DISCUSSION 
The goals of oncologic imaging are lesion detection, 
lesion characterization, evaluation of the extent of the 
neoplasm, staging for malignant lesions, and 
assessment of the therapeutic response. FDG-PET is 
most helpful to monitor patients with advanced-stage 
colorectal carcinoma that is associated with a poor 
prognosis [12]. 
Lubezky et al. evaluated FDG-PET and CT’s 
effectiveness and limitations in re-staging of patients 
with hepatic colorectal metastases following 
neoadjuvant chemotherapy. They also compared the 
outcomes of operations and the pathological findings of 
the patients. They divided the patients into two groups: 
the first group consisted of patients who received 
neoadjuvant chemotherapy, while the second group 
consisted of patients who underwent a direct resection. 
The FDG-PET and CT’s sensitivity in detecting 
colorectal metastases was found to be significantly 
higher in the first group compared to the second group. 
In patients that received bevacizumab in addition to 
chemotherapy, the PET and CT’s sensitivity in 
assessment of treatment response was significantly 
lower compared to those who underwent hepatic 
resection [13]. 
Kabbinavar et al. compared metastatic colorectal 
cancer patients treated with a regimen containing 
fluorouracil, leucovarine and bevacizumab to patients 
treated with a regimen containing fluorouracil, 
leucovarine and placebo. They reported the survival in 
the bevacizumab group was significantly better than 
placebo group [14]. Zoratto et al. also evaluated the 
efficacy of bevacizumab in the treatment of colorectal 
cancer patients, and reported that bevacizumab in 
combination with chemotherapy extended the life 
expectancy of metastatic colorectal cancer patients 
from 5 months to 2 years [15]. In a different study, 
Rossi et al. determined that colorectal cancer patients 
with only hepatic metastases responded better to 
combined chemotherapy and bevacizumab treatment 
than patients with extrahepatic metastases or multiple 
metastases. They also determined that 41.7% of 
patients had stable disease, 39.8% had partial 
response to treatment, 3.7% had a complete response 
to treatment and 14.8% had progressive disease [16]. 
The results of our study were similar to their study, with 
31.8% of patients responded to treatment, while 68.2% 
of patients did not respond to the treatment. According 
to the results of our study, mean SUVmax values of 
liver, abdominopelvic, lung and bone metastases were 
significantly decreased in patients who responded to 
chemotherapy and bevacizumab treatment, on the 
other hand those values were increased the patients 
who did not respond to the treatment.  
Bertolini et al. evaluated the effectiveness of 
FOLFOX6 and bevacizumab treatment in a study with 
21 colorectal cancer patients with liver metastases that 
were not fully resectable. They reported seeing 
complete response to treatment in 3 patients, partial 
response in 9 patients, while 1 patient had died due to 
toxicity. Sixteen of 21 patients were evaluated with 
PET-CT, and response to treatment was observed in 
11 patients (68.75%) with no response to treatment in 5 
patients (31.25%) [17].Their treatment response results 
were different from ours (31.8%).In the same study, 
Bertolini et al. evaluated the PET-CT scans of 16 
patients and determined that the mean SUVmax values 
of liver metastasis before treatment was ≥8.0, while the 
post-treatment mean SUVmax value was 5.2 [17]. In 
our study, the evaluation of PET-CT scans showed that 
the mean SUVmax of liver metastases before 
treatment was 7.66, while post-treatment mean 
SUVmax value was 8.80. Unlike Bertolini’s study, in our 
study the mean SUVmax values of post-treatment liver 
metastatic lesions increased. However, this increase 
was not statistically significant. In our study, we also 
compared the mean SUVmax values of hepatic, 
extrahepatic, abdominopelvic, lung, and bone 
metastatic foci before and after treatment in all 
patients. However, we did not find any significant 
difference between the pre-treatment and post-
treatment SUVmax values. We think that the 
bevacizumab’s low treatment response rate (31.8%) 
and the increase of the SUVmax values of patients with 
progressing disease might have increased the mean 
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SUVmax values. The patients were divided into two 
groups based on response to treatment, and box plot 
graphs were drawn to evaluate pre-treatment and post-
treatment SUVmax values. SUVmax values 
significantly decreased in patients who responded to 
treatment, and increased in patients who did not 
respond to treatment. These results were consistent 
with the Wahl et al. study. Wahl et al. compared solid 
tumors using RECIST and PERCIST criteria, and 
determined that assessing treatment response with 
metabolic response criteria yields more reliable results 
compared to anatomical assessment based on 
changes in size alone [18]. 
In a case study by Funaioli et al., a patient treated 
with bevacizumab was determined to have regression 
based on CT evaluation. However, re-evaluation with 
PET-CT showed a new metastatic lymph node, and 
thus the patient’s diagnosis was changed to a 
progressive disease. The results of this study point out 
that in metastatic colorectal cancer patients taking 
bevacizumab, response to treatment cannot be 
determined by anatomic evaluation with CT alone [19]. 
In our study, before treatment the number of metastatic 
lesions in the liver was 39, while that number after 
treatment increased to 45. Moreover, the average size 
of metastatic lesions in the liver prior to treatment was 
3.88 cm, and after treatment the average size of 
lesions increased to 5.58 cm. SUVmax values before 
and after the treatment were 7.66 and 8.80, 
respectively. 
Klinger et al. conducted a histological evaluation of 
the effect of bevacizumab treatment in patients with 
colorectal cancer and liver metastases. Patients were 
treated with XELOX/FOLFOX, and the study 
determined that bevacizumab was effective in 
significantly reducing the tumor growth and prolonging 
progression-free survival [20]. In our study, all of the 7 
patients (31.8%) that respond to therapy survived until 
the end of the study, while 9 out of 15 patients that did 
not respond to treatment have died at the end of the 
study. This relationship between survival and treatment 
was found to be statistically significant. 
A study Cerfolio et al. retrospectively evaluated 315 
patients with non-small cell lung cancer and measured 
their SUVmax values with PET imaging. The 
investigators evaluated all suspicious nodal and 
systemic localizations by biopsy and lymphadenectomy 
resections. Authors stated that in patients with early-
stage non-small cell lung cancer, SUVmax value was a 
stronger independent predictor of recurrence and 
survival than Classification of Malignant Tumors (TNM) 
staging [21].  
In our study we determined the pre-treatment and 
post-treatment mean SUVmax value of hepatic, 
extrahepatic abdominopelvic, lung and bone metastatic 
foci in all the patients. The pre-treatment and post-
treatment SUVmax values were 7.66 and 8.80 for 
hepatic, 11.19 and 13.97 for extrahepatic 
abdominopelvic, 4.22 and 6.39 for lung, and 8.90 and 
13.48 for bone metastases, respectively. When 
considering that 68.2% of patients did not respond to 
treatment, these results highlight an increase in the 
post-treatment SUVmax values and support other 
studies in the literature. 
In our study, we determined that one of the most 
important aspects of FDG-PET’s superiority over the 
conventional methods was its ability to detect distant 
extrahepatic metastases. The majority of extrahepatic 
metastases detected by FDG-PET were located in the 
lungs (40.9%), followed by extrahepatic 
abdominopelvic (peritoneum, mesentery, lymph nodes) 
(63.6%) and bone metastases (22.7%). Similarly, Lai et 
al. used FDG-PET to detect extrahepatic metastases 
that could not be detected by conventional methods in 
patients with metastatic colorectal cancer [22]. 
Moreover, Delbeke et al. also used FGD-PET and 
reported detecting all extrahepatic metastases with 
100% sensitivity in patients with metastatic colorectal 
cancer [23]. 
CONCLUSION 
PET-CT can distinguish the metabolic response to 
bevacizumab accompanied by chemotherapy before 
any anatomical changes can occur, and also has the 
ability to detect extrahepatic distant metastases. 
Therefore, we believe that PET-CT is a better approach 
for the evaluation of response to bevacizumab therapy 
in patients with metastatic colorectal cancer. 
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